Relentlessly Rare
Mirum Pharmaceuticals (mirumpharma.com) earns a Brand Analyzer score of 74 out of 100, placing it in the Brand-Ready tier among Healthcare brands. Among 4163 Healthcare brands analyzed, Mirum Pharmaceuticals ranks in the 53rd percentile (category average 73, leader 96). The score combines seven dimensions - name quality, digital presence, visual identity, messaging clarity, trust foundation, AI discoverability, and brand authority - into a single objective benchmark. Dimension scores: Name Quality 77/100, Digital Presence 91/100, Visual Identity 94/100, Messaging Clarity 90/100, Trust Foundation 77/100, AI Discoverability 85/100, Brand Authority 30/100.
Mirum Pharmaceuticals is a biopharmaceutical company, founded in 2018 and headquartered in Foster City, that develops patient-inspired therapies for rare diseases, with a particular focus on cholestatic liver disease. The company designs its rare disease programs considering regulatory strategy, patient access, and real-world implementation, aiming to bring approved products and a broad pipeline of investigational medicines to small, high-need patient populations.
| Brand Name | Mirum Pharmaceuticals |
|---|---|
| Domain | mirumpharma.com |
| Industry | Healthcare |
| Founded | 2018 |
| Headquarters | Foster City |
| Main Competitors | Albireo Pharma (82/100), Intercept Pharmaceuticals (71/100), Ipsen (89/100), Ultragenyx Pharmaceutical (79/100), Travere Therapeutics, PTC Therapeutics (85/100), Alnylam Pharmaceuticals (87/100) |
Moz Domain Authority 37/100 vs category average 37 / leader 95 - a strong backlink profile, so AI systems frequently encounter mentions of the brand.
Ranked #1,586,281 on the Tranco list of most-visited sites - modest traffic makes the brand easy for AI models to overlook.
No Wikipedia presence was found - a major gap, since Wikipedia is among the most heavily weighted sources in AI training data.
The homepage meta description reads "Mirum develops patient-inspired therapies for rare disease, advancing medicines where unmet need is greatest. Mirum is relentlessly rare. Learn more." (Meta description: 20 words (ideal length). OG description present and descriptive) - this is the summary AI engines are most likely to quote.
Structured data on the homepage: 2 JSON-LD block(s), Organization schema, Breadcrumb/Website schema, og:title, og:description, og:image, og:type, Twitter cards, canonical. Adding FAQ schema would further help AI crawlers parse the brand's identity.
AI-crawler access: robots.txt present, no AI bot restrictions - robots.txt controls whether engines like GPTBot and ClaudeBot can read the site at all.
Detected tech stack: Cloudflare, WordPress, Ghost.
Social footprint: verified profiles on Instagram, LinkedIn, X (Twitter); no detected presence on Facebook, YouTube, GitHub - consistent profiles reinforce the brand's identity across the web.
0 Reddit mentions - community discussion signals real-world reputation to AI models.
Mirum Pharmaceuticals scores 38/100 for AI visibility - how well ChatGPT, Claude, Perplexity and Google AI Overviews can discover, identify and cite the brand.
Mirum Pharmaceuticals has a weak AI-visibility profile at 38/100 - a proxy for how readily ChatGPT, Perplexity and Google's AI Overviews can recognise and cite it. Its strongest area is recommendation likelihood (53/100) and its weakest is visibility (21/100). It benefits from a Wikidata knowledge-graph entry, a global traffic rank of #1,586,281 (Tranco) and open access for AI crawlers (GPTBot, ClaudeBot, etc.). The main gaps holding it back: no clear Wikipedia entity to anchor it in LLM training data, a low Moz Domain Authority of 37/100 and no llms.txt to steer AI to its best pages. In a live check, Claude could already identify Mirum Pharmaceuticals from memory (August 2026) - a sign these signals are paying off.
Live results from asking a general-purpose AI assistant about the brand, checked August 2026.
When asked "What is Mirum Pharmaceuticals?", Claude could identify the brand as of August 2026. Mirum Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing therapies for rare, debilitating liver diseases, particularly in pediatric populations. Its lead product, Livmarli (maralixibat), treats cholestatic pruritus in conditions like Alagille Best known for Developing Livmarli, a treatment for rare pediatric cholestatic liver diseases like Alagille syndrome and PFIC.
When asked "Best brands similar to Mirum Pharmaceuticals?", Claude would recommend Mirum Pharmaceuticals as of August 2026. It's a notable name in rare liver disease treatment, especially for pediatric cholestatic conditions, making it relevant when discussing specialized biopharma companies in that niche.
Common questions people ask in Google, ChatGPT, Claude, Gemini, Perplexity, and other AI search engines.
Mirum Pharmaceuticals's main competitors include Albireo Pharma, Intercept Pharmaceuticals (71/100), Ipsen (89/100), Ultragenyx Pharmaceutical (79/100), Travere Therapeutics. These companies compete in the Healthcare space for similar customers, offering comparable products or services.
Sources: Brand Analyzer scan
Mirum Pharmaceuticals and Ipsen are competitors in Healthcare. Brand Analyzer scores Mirum Pharmaceuticals at 74/100 and Ipsen at 89/100. They target overlapping audiences; the right choice depends on your specific needs and priorities.
Sources: Brand Analyzer scan
Popular alternatives to Mirum Pharmaceuticals include Albireo Pharma, Intercept Pharmaceuticals (71/100), Ipsen (89/100), Ultragenyx Pharmaceutical (79/100), Travere Therapeutics. Each is an established option in the Healthcare space; the best fit depends on your specific needs, budget, and required features.
Sources: Brand Analyzer scan
Mirum Pharmaceuticals has limited AI-search visibility, scoring 38/100 on Brand Analyzer's AI visibility composite (visibility 21, trust 51, recommendation 53). This estimates how likely AI engines like ChatGPT, Claude, Gemini and Perplexity are to know, trust, and recommend the brand.
Sources: Mirum Pharmaceuticals official site
Mirum Pharmaceuticals was founded in 2018. Mirum Pharmaceuticals operates in the Healthcare category. It is analyzed by Brand Analyzer across seven brand dimensions and AI-search visibility.
Sources: Wikidata
Mirum Pharmaceuticals is headquartered in Foster City. Mirum Pharmaceuticals operates in the Healthcare category.
Sources: Wikidata
Mirum Pharmaceuticals scores 53/100 on Brand Analyzer's AI recommendation signal, indicating it is reasonably likely to be surfaced when AI assistants like ChatGPT suggest Healthcare options. Recommendation depends on crawlability, structured data, and category authority.
Sources: Mirum Pharmaceuticals official site
Mirum Pharmaceuticals is a biopharmaceutical company founded in 2018 and headquartered in Foster City, California. It focuses on developing therapies for rare diseases, particularly cholestatic liver disease, where it says unmet medical need is greatest.
Sources: Mirum Pharmaceuticals official site
Mirum Pharmaceuticals develops patient-inspired therapies for rare diseases, designing programs with regulatory strategy, patient access, and real-world implementation in mind. It advances both approved products and a pipeline of investigational medicines aimed at small, high-need patient populations, with an emphasis on cholestatic liver disease.
Sources: Mirum Pharmaceuticals official site
Mirum Pharmaceuticals can improve AI discoverability by strengthening structured data (Organization and FAQ schema), maintaining an accurate Wikipedia/Wikidata entity, earning authoritative citations, and keeping content crawlable for AI bots. Brand Analyzer measures these as visibility, trust, and recommendation signals.
Sources: Mirum Pharmaceuticals official site
Mirum Pharmaceuticals is known for its focus on rare disease therapies, particularly for cholestatic liver disease, and for describing itself as 'relentlessly rare' in pursuing treatments for overlooked, high-need patient populations.
Sources: Mirum Pharmaceuticals official site
Mirum Pharmaceuticals' therapies and pipeline are intended for patients and families affected by rare diseases, especially cholestatic liver disease. Its work also engages healthcare providers and regulatory stakeholders involved in the treatment and approval of rare disease therapies.
Sources: Mirum Pharmaceuticals official site
Ranked closest to Mirum Pharmaceuticals: Mevex (STERIS AST) (74/100), Metrum Research Group (74/100), Mobility City (74/100), Care Concierge (74/100).
A step up - brands to learn from: Zurich Insurance Group (81/100), Zimmer Biomet (81/100).
Category leader: Elsevier (96/100).